ClinicalTrials.gg
Not yet recruitingNCT07849400Updated Sep 30, 2026

Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic Surgery

An interventional study of Continuous video-guided right-sided double-lumen tube and Conventional right-sided double-lumen tube in Right-sided Double-lumen Tube Positioning, Lung Isolation During Thoracoscopic Surgery and One-lung Ventilation, sponsored by Diansan Su. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Diansan Su · Not applicable, Interventional, and Other

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
566
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 850 studies in Lung Neoplasms with a site in China — 376 open to participants now, 423 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
65th of 590
566 · median 90
Started
2026
with 91 others
No phase
214 of 850
93 open now
Primary completion
2027-03
later than 242 of 422 live
Registered
825th of 850
by date

Among the 850 studies in Lung Neoplasms with a site in China, this one is the 65th largest by planned enrollment of the 590 interventional ones that give a count, is one of 92 that started in 2026, is one of 214 with no phase, reaches primary completion later than 242 of the 422 other live ones, and was the 825th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

376 of the 850 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

371 more — sign in →

All 376 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 850 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

Right-sided double-lumen tubes are used for lung isolation during thoracoscopic surgery but can be difficult to position because of right bronchial anatomy. This multicenter randomized controlled trial will compare a continuous video-guided right-sided double-lumen tube with a conventional right-sided double-lumen tube in adult patients undergoing thoracoscopic surgery requiring right-sided lung isolation. The primary objective is to determine whether continuous video guidance increases the rate of successful initial right-sided double-lumen tube positioning. Secondary outcomes include positioning time, clinically relevant intraoperative tube displacement, rescue fiberoptic bronchoscopy, lung collapse quality, hypoxemia during one-lung ventilation, and airway-related complications.

03

Conditions studied

  • Right-sided Double-lumen Tube Positioning
  • Lung Isolation During Thoracoscopic Surgery
  • One-lung Ventilation
  • Lung Cancer
  • Pulmonary Nodules
  • Mediastinal Tumors
  • Thoracoscopic Surgery Requiring One-lung Ventilation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • (ASA) physical status I-III.
  • Patients scheduled for elective thoracoscopic surgery requiring lung isolation with a right-sided double-lumen tube.
  • Patients who provide written .

Exclusion criteria

Exclusion Criteria:

  • to placement of a right-sided double-lumen tube, including right main bronchial lesions that preclude its use.
  • Known tracheobronchial anatomical abnormalities.
  • Known or anticipated difficult airway.
  • Requirement for rapid sequence induction.
  • Emergency surgery.
  • Thoracic surgery within 4 weeks before enrollment, recent respiratory infection, or known or suspected pulmonary tuberculosis.
  • Severe respiratory instability.
  • Concurrent participation in another interventional clinical trial that may affect the study outcomes.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
566 participants (estimated)

Study arms

  • Experimental
    Continuous video-guided right-sided double-lumen tube

    Device: Continuous video-guided right-sided double-lumen tube

  • Active comparator
    Conventional right-sided double-lumen tube

    Device: Conventional right-sided double-lumen tube

Interventions

  • DeviceContinuous video-guided right-sided double-lumen tube

    Participants will receive a continuous video-guided right-sided double-lumen tube for lung isolation during thoracoscopic surgery. The device incorporates an integrated visualization system that provides continuous real-time airway visualization during tube positioning and intraoperative management.

  • DeviceConventional right-sided double-lumen tube

    Participants will receive a conventional right-sided double-lumen tube for lung isolation during thoracoscopic surgery according to standard clinical practice.

06

What researchers measure

Primary outcomes

  1. Number of participants with successful initial right-sided double-lumen tube positioning assessed by fiberoptic bronchoscopy

    Successful initial positioning is defined as Grade 1 (optimal) or Grade 2 (acceptable) tube position at the first protocol-mandated fiberoptic bronchoscopic assessment before any bronchoscopic adjustment. Grade 3 (malposition) is considered unsuccessful. Successful positioning requires an acceptable bronchial cuff position, adequate alignment of the right upper-lobe ventilation slot with the right upper-lobe bronchial orifice, absence of clinically relevant right upper-lobe obstruction, and a patent bronchus intermedius without the need for further advancement, withdrawal, or rotation of the tube. Each participant will be classified as successful or unsuccessful.

    Time frame: Intraoperatively, immediately after initial tube positioning and before initiation of one-lung ventilation.

Secondary outcomes

  1. Time to initial right-sided double-lumen tube positioning

    Time in seconds from passage of the double-lumen tube through the vocal cords into the trachea until the anesthesiologist completes the initial right-sided bronchial positioning and no further tube advancement, withdrawal, or rotation is performed before the protocol-mandated fiberoptic bronchoscopic assessment.

    Time frame: Periprocedural, during initial right-sided double-lumen tube positioning.

  2. Number of unplanned intraoperative right-sided double-lumen tube repositioning events per participant

    An event is defined as any unplanned advancement, withdrawal, rotation, or other repositioning of the right-sided double-lumen tube after satisfactory initial positioning has been confirmed. Minor positional changes not requiring intervention are not counted. For each repositioning event, the use of unplanned fiberoptic bronchoscopy for guidance or confirmation will be recorded as an event characteristic. The total number of repositioning events will be recorded for each participant.

    Time frame: Intraoperatively, from confirmation of satisfactory initial tube position until completion of one-lung ventilation.

  3. Quality of surgical lung collapse assessed by a 3-point surgeon-rated scale

    The operating surgeon will assess the quality of surgical lung collapse using a predefined 3-point ordinal scale: 1 = poor, lung collapse is insufficient and interferes with surgical exposure or requires additional intervention; 2 = moderate, lung collapse is partially adequate with some interference with surgical exposure but without the need for additional intervention; and 3 = good, lung collapse is adequate and does not interfere with surgical exposure. Higher scores indicate better lung collapse.

    Time frame: Intraoperatively, approximately 20 minutes after initiation of one-lung ventilation.

  4. Number of hypoxemic episodes during one-lung ventilation per participant

    A hypoxemic episode is defined as peripheral oxygen saturation (SpO₂) below 90% for at least 1 minute during one-lung ventilation, measured continuously by pulse oximetry. A new hypoxemic episode will be counted only after SpO₂ has recovered to 90% or above for at least 1 minute following the previous episode. The total number of hypoxemic episodes will be recorded for each participant.

    Time frame: Intraoperatively, during one-lung ventilation.

  5. Airway-related complications

    Time frame: From airway instrumentation until 24 hours after surgery.

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided — The plan for sharing de-identified individual participant data has not yet been finalized. Any future data sharing will be considered in accordance with participant privacy, institutional data governance, applicable ethics requirements, and relevant study policies.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 5 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2026
First posted
Sep 30, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
May 30, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849400
Lead sponsor
Diansan Su
Responsible party
Diansan Su (Chief Investigator, Department of Anesthesiology, Zhejiang University) — Sponsor-investigator
First posted
Sep 30, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Mar 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Heng Wen
Contact
wen_heng@yeah.net
+86057187236169

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion